|
Market Closed -
Nasdaq
16:00:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 25.49 USD | -2.45% |
|
-5.45% | +10.83% |
| 08-05 | Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed | MT |
| 08-04 | Ultragenyx Pharmaceutical Inc., Q2 2026 Earnings Call, Aug 04, 2026 |
Chart: Technical Analysis
Stock exchange
Nasdaq
RARE 25.49 $
-2.45%
45.71M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| RARE | 25.49USD | -2.45% | 45.71M $ | |
CBOE
| RARE | 25.49USD | -2.37% | 968K $ | |
|
Tradegate
| UP0 | 22.26EUR | +1.04% | 823.62 € | |
|
London S.E.
| 0LIF | 24.57USD | -31.52% | 368.55 $ | |
|
Mexican S.E.
| RARE * | 450.00MXN | -60.89% | 6.3K $ | |
|
Deutsche Boerse AG
| UP0 | 22.10EUR | -0.94% | 0 € | |
|
Börse Stuttgart
| UP0 | 22.12EUR | +1.42% | 0 € | |
|
Berne S.E.
| UP0 | 20.52CHF | -4.25% | 0 CHF | |
|
Boerse Muenchen
| UP0 | 22.12EUR | +0.82% | 0 € | |
Sao Paulo
| R2AR34 | 13.62BRL | +5.83% | 272.4 R$ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 28.62 | 35.87 | 36.38 |
| Spread/Res. | -10.94% | -28.94% | -29.93% |
| Spread/Supp. | +2.33% | +37.78% | +31.53% |
| Support | 24.91 | 18.5 | 19.38 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- RARE Stock
- Charts Ultragenyx Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
